<DOC>
	<DOCNO>NCT02306629</DOCNO>
	<brief_summary>To assess absolute bioavailability , dose proportionality , pharmacokinetics , safety tolerability epratuzumab compare give subcutaneous ( sc ) injection give intravenous ( iv ) infusion Caucasian Japanese healthy volunteer .</brief_summary>
	<brief_title>Study Compare Properties Epratuzumab When Given Injection Under Skin Directly Into Blood</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subject male female . At Screening Visit , subject 18 year 50 year , inclusive ( Caucasian subject ) , 20 year 50 year ( Japanese subject ) Subject must good health ( physically mentally ) determine investigator basis medical history Subject body weight 45 kg 90 kg , inclusive , body mass index ( BMI ) 18.0 kg/m2 29.9 kg/m2 , inclusive Japanese subject define person carry Japanese passport , descendant 4 Japanese grandparent outside Japan 5 year prior screen Females childbearing potential require negative serum pregnancy test Screening Visit must agree use acceptable method birth control study period 3 month administration investigational medicinal product ( IMP ) Male subject must agree use acceptable method contraception study least 3 month receive IMP unless undergone vasectomy Subject donate blood ( include participation another clinical study ) suffer blood loss ( â‰¥450 mL ) &lt; 60 day prior dose , donate platelet &lt; 14 day prior dose Subject active malignancy history malignancy Subject history severe multiple allergy Subject history chronic infection , recent serious lifethreatening infection Subject recurrent history active systemic/respiratory infection due fungal , parasitic , mycotic pathogen Subject positive HBsAg , antiHCV antiHIV test result Screening Period Subject history concurrent clinically significant illness , medical condition , laboratory abnormality , investigator 's opinion , could affect safety subject upon exposure epratuzumab confound result study Female subject breast feeding , pregnant , plan become pregnant study within 3 month follow dose IMP Subjects immunocompromised A confirm positive urine drug screen Subject history substance abuse , drug addiction , alcoholism within 3 year prior study admission Subject unable unwilling stop smoking inpatient stay Subject previous exposure , participated study , antiBcell therapy Subject medical condition require chronic medication Subject receive live vaccine month prior administration IMP schedule expect receive live vaccine study period 3 month administration IMP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>